Author

E. Chatelain

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:metagenomics· 1 Organism:virus· 1

Frequent Co-Authors

F. Escudie· 4 shared I. Scandale· 4 shared A. Nougairede· 2 shared C. Mowbray· 2 shared F. Touret· 2 shared J. Tarning· 2 shared J.-S. Driouich· 2 shared L. Fraisse· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

F. Escudie

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains

H. S. Bouzidi, J.-S. Driouich, R. Klitting, O. Bernadin, G. Piorkowski, R. Amaral, L. Fraisse, C. E. Mowbray, I. Scandale, F. Escudie, E. Chatelain, X. de Lamballerie, A. Nougairede, F. Touret

The paper generates and evaluates SARS-CoV-2 mutants resistant to protease inhibitors nirmatrelvir and ensitrelvir, showing in vitro and in vivo resistance and linking M49L mutation prevalence to Xocova(R) use.

bioRxiv · Nov 22, 2023Microbiology

Combinatorial Regimens Augment Drug Monotherapy for SARS-CoV-2 Clearance in Mice

I. Ullah, F. Escudie, I. Scandale, Z. Gilani, G. Gendron-Lepage, F. Gaudette, C. Mowbray, L. Fraisse, R. Bazin, A. Finzi, W. Mothes, P. Kumar, E. Chatelain, P. D. Uchil

This study evaluates DAAs and their combinations for SARS-CoV-2 clearance in mice, finding that dual-targeting regimens outperform monotherapies.

bioRxiv · May 31, 2023 · PreprintMicrobiology

Pre-clinical evaluation of antiviral activity of nitazoxanide against Sars-CoV-2

J.-S. Driouich, M. Cochin, F. Touret, P.-R. Petit, M. Gilles, G. Moureau, K. Barthelemy, C. Laprie, T. Wattanakul, P. Chotsiri, R. M. Hoglund, J. Tarning, F. Escudie, I. Scandale, E. Chatelain, , A. Nougairede

This study evaluates nitazoxanide's antiviral activity against SARS-CoV-2 in vitro and in vivo, finding that its standard dosage is ineffective due to insufficient drug concentration in target organs.

bioRxiv · Dec 17, 2021Pathology

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern

R. Abdelnabi, C. S.-Y. Foo, D. Jochmans, L. Vangeel, S. De Jonghe, P. Augustijns, R. Mols, B. Weynand, T. Wattanakul, R. Hoglund, J. Tarning, C. Mowbray, P. Sjo, F. Escudie, I. Scandale, , J. Neyts

PF-07321332, an oral protease inhibitor, effectively protects Syrian hamsters against SARS-CoV-2 variants of concern, including beta and delta, by preventing infection and transmission.

bioRxiv · Nov 4, 2021Microbiology